Millie Wang

546 total citations
11 papers, 269 citations indexed

About

Millie Wang is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Rheumatology. According to data from OpenAlex, Millie Wang has authored 11 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Physiology and 3 papers in Rheumatology. Recurrent topics in Millie Wang's work include Asthma and respiratory diseases (8 papers), Respiratory and Cough-Related Research (6 papers) and Inhalation and Respiratory Drug Delivery (4 papers). Millie Wang is often cited by papers focused on Asthma and respiratory diseases (8 papers), Respiratory and Cough-Related Research (6 papers) and Inhalation and Respiratory Drug Delivery (4 papers). Millie Wang collaborates with scholars based in United Kingdom, United States and Sweden. Millie Wang's co-authors include Gene Colice, John Mo, Michael E. Weinblatt, Heather Wray, Arthur Kavanaugh, Mark C. Genovese, Désirée van der Heijde, Sally Hollis, David Millson and Karin Bowen and has published in prestigious journals such as European Respiratory Journal, BMJ Open and Arthritis & Rheumatology.

In The Last Decade

Millie Wang

11 papers receiving 260 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Millie Wang United Kingdom	7	101	88	74	49	42	11	269
Geraldine A. Goss Australia	5	119 1.2×	105 1.2×	74 1.0×	14 0.3×	15 0.4×	6	333
Nadia Harun Australia	6	15 0.1×	25 0.3×	70 0.9×	41 0.8×	64 1.5×	6	334
Remi Sumiyoshi Japan	11	49 0.5×	49 0.6×	105 1.4×	140 2.9×	52 1.2×	50	359
Francesco Caprioni Italy	8	72 0.7×	56 0.6×	34 0.5×	25 0.5×	6 0.1×	13	331
Maria Elisabetta Fratto Italy	11	19 0.2×	62 0.7×	37 0.5×	43 0.9×	7 0.2×	14	372
Lola Luo United States	8	32 0.3×	69 0.8×	61 0.8×	19 0.4×	164 3.9×	8	403
Joanna Vitfell-Rasmussen United Kingdom	5	43 0.4×	94 1.1×	15 0.2×	10 0.2×	14 0.3×	6	337
Jiadai Xu China	11	17 0.2×	17 0.2×	54 0.7×	9 0.2×	107 2.5×	43	288
Nobuyoshi Takeuchi Japan	7	9 0.1×	69 0.8×	23 0.3×	80 1.6×	52 1.2×	25	322
Takayuki Shimose Japan	8	28 0.3×	123 1.4×	18 0.2×	13 0.3×	26 0.6×	20	239

Countries citing papers authored by Millie Wang

Since Specialization

Citations

This map shows the geographic impact of Millie Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Millie Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Millie Wang more than expected).

Fields of papers citing papers by Millie Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Millie Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Millie Wang. The network helps show where Millie Wang may publish in the future.

Co-authorship network of co-authors of Millie Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Millie Wang. A scholar is included among the top collaborators of Millie Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Millie Wang. Millie Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Weinblatt, Michael E., Peter C. Taylor, Iain B. McInnes, et al.. (2025). Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X). BMJ Open. 15(3). e088869–e088869. 1 indexed citations

Brusselle, Guy, Stephanie Korn, Piotr Kuna, et al.. (2018). Oral corticosteroid (OCS)-sparing effect of tralokinumab in severe, uncontrolled asthma: the TROPOS study. PA602–PA602. 2 indexed citations

Busse, William W., Guy Brusselle, Stephanie Korn, et al.. (2018). Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. European Respiratory Journal. 53(2). 1800948–1800948. 49 indexed citations

Panettieri, Reynold A., Millie Wang, Martin Braddock, Karin Bowen, & Gene Colice. (2018). Tralokinumab for the Treatment of Severe, Uncontrolled Asthma: The ATMOSPHERE Clinical Development Program. Immunotherapy. 10(6). 473–490. 18 indexed citations

O’Byrne, Paul M., J. Mark FitzGerald, Eric D. Bateman, et al.. (2018). Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. OA1680–OA1680. 1 indexed citations

Brightling, Christopher E., Millie Wang, Martin Braddock, et al.. (2015). MESOS: considerations in designing a mechanistic study for a biologic used to treat asthma. Clinical Investigation. 5(8). 713–722. 5 indexed citations

Busse, William W., Millie Wang, Jennifer A. Gibson, et al.. (2015). TROPOS: designing a clinical trial to evaluate the oral corticosteroid-sparing effect of a biologic in severe asthma. Clinical Investigation. 5(8). 723–730. 11 indexed citations

Kitas, George D., Gabriel Abreu, Krystyna Jedrychowicz‐Rosiak, et al.. (2014). The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. Journal of the American Society of Hypertension. 8(11). 780–790. 9 indexed citations

Weinblatt, Michael E., Mark C. Genovese, Meilien Ho, et al.. (2014). Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study. Arthritis & Rheumatology. 66(12). 3255–3264. 88 indexed citations

10.

Dahl, Ronald, Ingrid Louise Titlestad, Ari Lindqvist, et al.. (2012). Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomised controlled trial. Pulmonary Pharmacology & Therapeutics. 25(2). 169–177. 59 indexed citations

11.

Magnussen, H, Henrik Watz, Anne Kirsten, et al.. (2011). Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: A randomised controlled 6-week trial. Pulmonary Pharmacology & Therapeutics. 24(5). 563–570. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact